Viridian Therapeutics (1S1) Price & Analysis

1 Followers

1S1 Stock Chart & Stats

€16.80

€0.10(0.60%)

At close: Jul 24 4:00 PM EDT

€16.80

€0.10(0.60%)

Day’s Range― - ―

52-Week Range€11.20 - €28.58

Previous CloseN/A

Volume0.00

Average Volume (3M)107.00

Market Cap

€1.81B

Enterprise Value€1.42K

Total Cash (Recent Filing)€762.18M

Total Debt (Recent Filing)€51.17M

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Aug 12, 2026

EPS Estimate

-0.89

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.48

Shares Outstanding110,427,680

10 Day Avg. Volume22

30 Day Avg. Volume107

Financial Highlights & Ratios

PEG Ratio0.57

Price to Book (P/B)3.65

Price to Sales (P/S)37.25

P/FCF Ratio-9.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€29.39

Price Target Upside74.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-3.33

Revenue Forecast (FY)€18.70M

Bulls Say, Bears Say

Bulls Say

Pivotal Phase 3 Success / Regulatory PathTwo successful pivotal trials (REVEAL-1 and REVEAL-2) materially de-risk regulatory approval for elegrobart, enabling a BLA pathway and potential U.S./EU launches. This strengthens the company’s long-term commercial prospects and gives durable leverage for market entry and payer discussions.

Secured Commercial Manufacturing CapacityA multi-year, non-exclusive manufacturing pact with WuXi secures scalable drug substance and product capacity for a potential launch, reducing operational execution risk. Rolling forecasts and fixed service fees through 2026 improve predictability around supply economics and launch readiness.

Improved Capital Structure And Low LeverageLow leverage and a strengthened capital base (including recent $359M financing and Hercules loan repayment) provide financial flexibility to fund regulatory filings, commercialization prep, and R&D. Reduced interest obligations and a larger cash buffer lower near-term refinancing risk.

Bears Say

High Cash BurnSustained negative operating and free cash flow at ~-$300M TTM creates ongoing reliance on capital markets to fund operations. This persistent burn increases dilution risk, constrains discretionary investment, and pressures management to prioritize near-term funding over long-term optionality.

Large Net Losses And Negative MarginsVery large net losses and negative operating margins reflect a high fixed-cost R&D and SG&A structure relative to current revenue. Even with revenue gains, returning to sustainable profitability will require successful product launches or material cost reduction, a multiyear challenge.

No Commercial Revenue; Clinical-Stage DependenceAs a clinical-stage biotech without marketed products, long-term value hinges on approvals, reimbursement, and commercial execution. Until a product generates sustained sales, the company remains exposed to regulatory, payer and launch execution risks and recurring financing cycles.

Viridian Therapeutics News

“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market

What to make of the markets today? The biggest story in recent months has been the conflict in...

19d ago

AEIS

VRDN

Viridian Therapeutics price target raised to $43 from $32 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on Viridian Therapeutics (VRDN) to $43 from $32 and...

1M ago

VRDN

Viridian Therapeutics price target raised to $38 from $35 at Truist

Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $35 and keeps a Buy...

1M ago

VRDN

Viridian Therapeutics price target raised to $35 from $34 at RBC Capital

RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $35 from $34 and keeps an...

1M ago

VRDN

Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $35 and keeps a...

1M ago

VRDN

Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Viridian Therapeutics, retaining the price target of...

1M ago

VRDN

Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform

As previously reported, Wells Fargo analyst Derek Archila upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with...

1M ago

VRDN

Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with a price target of $31, up...

1M ago

VRDN

Analyst Initiates Buy on Viridian, Citing Competitive Lumvoa Launch and Pipeline-Driven Long-Term Growth

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on VRDN stock, giving a Buy rating...

1M ago

VRDN

Viridian Therapeutics announces FDA approval, launch of Lumvoa

Viridian Therapeutics (VRDN) announced that the U.S. FDA has approved Lumvoa for the treatment of thyroid eye disease....

1M ago

VRDN

Viridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for Investors

Viridian Therapeutics, Inc. ($VRDN) announced an update on their ongoing clinical study. This phase 3 study, officially titled...

1M ago

VRDN

Viridian Therapeutics Shareholders Approve Directors and Governance Items

Viridian Therapeutics ( ($VRDN) ) just unveiled an update. On June 2, 2026, Viridian Therapeutics held its 2026...

2M ago

VRDN

Viridian Therapeutics Fully Repays Loan, Ends Agreement

Viridian Therapeutics ( ($VRDN) ) has shared an update. On May 27, 2026, Viridian Therapeutics, Inc. fully repaid...

2M ago

VRDN

Viridian Therapeutics secures WuXi deal for veligrotug manufacturing

Viridian Therapeutics ( ($VRDN) ) just unveiled an update. On May 24, 2026, Viridian Therapeutics, Inc. entered into...

2M ago

VRDN

1S1 FAQ

What was Viridian Therapeutics, Inc.’s price range in the past 12 months?

Viridian Therapeutics, Inc. lowest stock price was €11.20 and its highest was €28.58 in the past 12 months.

What is Viridian Therapeutics, Inc.’s market cap?

Viridian Therapeutics, Inc.’s market cap is €1.81B.

When is Viridian Therapeutics, Inc.’s upcoming earnings report date?

Viridian Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.

How were Viridian Therapeutics, Inc.’s earnings last quarter?

Viridian Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -€0.78 earnings per share for the quarter, beating the consensus estimate of -€0.937 by €0.157.

Is Viridian Therapeutics, Inc. overvalued?

According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viridian Therapeutics, Inc. pay dividends?

Viridian Therapeutics, Inc. does not currently pay dividends.

What is Viridian Therapeutics, Inc.’s EPS estimate?

Viridian Therapeutics, Inc.’s EPS estimate is -0.89.

How many shares outstanding does Viridian Therapeutics, Inc. have?

Viridian Therapeutics, Inc. has 110,427,680 shares outstanding.

What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?

Viridian Therapeutics, Inc. reported an EPS of -€0.78 in its last earnings report, beating expectations of -€0.937. Following the earnings report the stock price went up 5.31%.

Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?

Currently, no hedge funds are holding shares in DE:1S1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viridian Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

19.37%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Viridian Therapeutics (1S1) Earnings & Revenues

Historic Earnings Reports

1S1 Stock 12 Month Forecast

Average Price Target

€29.39

▲(74.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","17":"€17","24":"€24","31":"€31","38":"€38"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37.27258318,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.39254445272727,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€29.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.06969372,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.07</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,17,24,31,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.3,18.836352552307694,20.372705104615385,21.90905765692308,23.44541020923077,24.981762761538462,26.518115313846153,28.054467866153846,29.59082041846154,31.12717297076923,32.66352552307692,34.19987807538462,35.73623062769231,{"y":37.27258318,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.3,18.230195727132866,19.160391454265735,20.0905871813986,21.02078290853147,21.950978635664335,22.881174362797204,23.81137008993007,24.741565817062938,25.671761544195803,26.601957271328672,27.532152998461537,28.462348725594403,{"y":29.39254445272727,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.3,17.436130286153848,17.572260572307695,17.708390858461538,17.844521144615385,17.980651430769232,18.11678171692308,18.252912003076922,18.38904228923077,18.525172575384616,18.661302861538463,18.797433147692306,18.933563433846153,{"y":19.06969372,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.455,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.995,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.485,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >